Prevalence of cardiovascular disease in type 2 diabetes: A systematic literature review of scientific evidence from across the world in 2007-2017

Cardiovascular Diabetology

Volumn 17, Issue 1, 2018, Pages

  Einarson, Thomas R ^a   Acs, Annabel ^b   Ludwig, Craig ^b   Panton, Ulrik H ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b Last Mile P   (Denmark)

^c NOVO NORDISK A S   (Denmark)

Author keywords

Angina; Cardiovascular disease; Ischemic heart disease; Myocardial infarction; Prevalence; Stroke; Type 2 diabetes

Indexed keywords

ANGINA PECTORIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CHECKLIST; CHINA; COMORBIDITY; CONSENSUS; CORONARY ARTERY DISEASE; DISEASE DURATION; EMBASE; EUROPE; GROUPS BY AGE; HEART FAILURE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MEDICAL LITERATURE; MEDLINE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREVALENCE; PUBLICATION; REVIEW; SEX DIFFERENCE; SYSTEMATIC REVIEW; ADULT; AGED; FEMALE; GLOBAL HEALTH; MALE; MIDDLE AGED; MORTALITY; PROGNOSIS; RISK FACTOR; TIME FACTOR; TRENDS;

ADULT; AGED; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; COMORBIDITY; DIABETES MELLITUS, TYPE 2; FEMALE; GLOBAL HEALTH; HUMANS; MALE; MIDDLE AGED; PREVALENCE; PROGNOSIS; RISK FACTORS; TIME FACTORS;

EID: 85048255721     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/s12933-018-0728-6     Document Type: Review

References (118)

1. International Diabetes Federation. idf diabetes atlas. 7th ed. Brussels: International Diabetes Federation; 2015.
2. Abraham TM, Pencina KM, Pencina MJ, Fox CS. Trends in diabetes incidence: the Framingham heart study. Diab Care. 2015;38:482-7.
3. International Diabetes Federation. Diabetes and cardiovascular disease. Brussels: International Diabetes Federation; 2016. p. 1-144.
4. Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Angelantonio D, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. emerging risk factors collaboration. Lancet. 2010;375:2215-22.
5. Singh GM, Danaei G, Farzadfar F, Stevens GA, Woodward M, Wormser D, Kaptoge S, Whitlock G, Qiao Q, Lewington S. The age-specific quantitative effects of metabolic risk factors on cardiovascular diseases and diabetes: a pooled analysis. PLoS ONE. 2013;8:e65174.
6. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-34.
7. Fox CS, Pencina MJ, Wilson PW, Paynter NP, Vasan RS, D'Agostino RB. Lifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the Framingham heart study. Diab Care. 2008;31:1582-4.
8. Van Hateren KJ, Landman GW, Kleefstra N, Logtenberg SJ, Groenier KH, Kamper AM, Houweling ST, Bilo HJ. The lipid profile and mortality risk in elderly type 2 diabetic patients: a 10-year follow-up study (ZODIAC-13). PLoS ONE. 2009;4:e8464.
9. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-86.
10. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643-53.
11. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560-72.
12. UK Prospective Diabetes Study. (UKPDS) Group: intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK prospective diabetes study (UKPDS) group. Lancet. 1998;352:837-53.
13. Action to Control Cardiovascular Risk in Diabetes Study. Group: effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545-59.
14. Rydén L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, Deaton C, Escaned J, Hammes H-P, Huikuri H. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD-summary. Diab Vasc Dis Res. 2014;11:133-73.
15. Schnell O, Rydén L, Standl E, Ceriello A. Updates on cardiovascular outcome trials in diabetes. Cardiovasc Diabetol. 2017;16:128.
16. Food and Drug Administration: Guidance for industry: diabetes mellitus-evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. US Department of Health and Human Services. 2008.
17. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834-44.
18. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;2016:311-22.
19. Sanon VP, Patel S, Sanon S, Rodriguez R, Pham SV, Chilton R. Differential cardiovascular profiles of sodium-glucose cotransporter 2 inhibitors: critical evaluation of empagliflozin. Ther Clin Risk Manag. 2017;13:603.
20. Trujillo JM, Nuffer WA. Impact of sodium-glucose cotransporter 2 inhibitors on nonglycemic outcomes in patients with type 2 diabetes. Pharmacotherapy. 2017;37:481-91.
21. Schnell O, Cappuccio F, Genovese S, Standl E, Valensi P, Ceriello A. Type 1 diabetes and cardiovascular disease. Cardiovasc Diabetol. 2013;12:156.
22. Ford ES, Zhao G, Li C. Pre-diabetes and the risk for cardiovascular disease. J Am Coll Cardiol. 2010;55:1310-7.
23. Saquib N, Saquib J, Ahmed T, Khanam MA, Cullen MR. Cardiovascular diseases and type 2 diabetes in Bangladesh: a systematic review and meta-analysis of studies between 1995 and 2010. BMC Public Health. 2012;12:434.
24. Moher D, Liberati A, Tetzlaff J, Altman DG. Group. P: preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264-9.
25. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, Initiative S. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Int J Surg. 2014;12:1495-9.
26. Bhatti GK, Bhadada SK, Vijayvergiya R, Mastana SS, Bhatti JS. Metabolic syndrome and risk of major coronary events among the urban diabetic patients: North Indian Diabetes and cardiovascular disease study-NIDCVD-2. J Diab Complications. 2016;30:72-8.
27. Collier A, Ghosh S, Hair M, Waugh N. Impact of socioeconomic status and gender on glycaemic control, cardiovascular risk factors and diabetes complications in type 1 and 2 diabetes: a population based analysis from a Scottish region. Diab Metab. 2015;41:145-51.
28. Tan ED, Davis WA, Davis TM. Changes in characteristics and management of Asian and Anglo-Celts with type 2 diabetes over a 15-year period in an urban Australian community: the fremantle diabetes study. J Diab. 2016;8:139-47.
29. Shestakova M: Dynamics in prevalence of diabetes, diabetic complications and quality of diabetes care in Russian Federation in 2014-2015 by data of national diabetes register. In: Conference: 52nd annual meeting of the european association for the study of diabetes, EASD. 2016. p. 309.
30. Alwakeel JS, Sulimani R, Al-Asaad H, Al-Harbi A, Tarif N, Al-Suwaida A, Al-Mohaya S, Isnani AC, Alam A, Hammad D. Diabetes complications in 1952 type 2 diabetes mellitus patients managed in a single institution in Saudi Arabia. Ann Saudi Med. 2008;28:260-6.
31. Cardoso C, Salles G. Gross proteinuria is a strong risk predictor for cardiovascular mortality in Brazilian type 2 diabetic patients. Braz J Med Biol Res. 2008;41:674-80.
32. Carnethon MR, Biggs ML, Barzilay J, Kuller LH, Mozaffarian D, Mukamal K, Smith NL, Siscovick D. Diabetes and coronary heart disease as risk factors for mortality in older adults. Am J Med. 2010;123:556.
33. Eeg-Olofsson K, Cederholm J, Nilsson PM, Zethelius B, Svensson AM, Gudbjörnsdóttir S, Eliasson B. New aspects of HbA1c as a risk factor for cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR). J Intern Med. 2010;268:471-82.
34. Malik MO, Govan L, Petrie JR, Ghouri N, Leese G, Fischbacher C, Colhoun H, Philip S, Wild S, McCrimmon R, et al. Ethnicity and risk of cardiovascular disease (CVD): 4.8 year follow-up of patients with type 2 diabetes living in Scotland. Diabetologia. 2015;58:716-25.
35. Salinero-Fort MA, Andres-Rebollo FJ, Burgos-Lunar C, Abanades-Herranz JC, Carrillo-de-Santa-Pau E, Chico-Moraleja RM, Jimenez-Garcia R, Lopez-de-Andres A, Gomez-Campelo P. Cardiovascular and all-cause mortality in patients with type 2 diabetes mellitus in the MADIABETES Cohort Study: association with chronic kidney disease. J Diab Complications. 2016;30:227-36.
36. Menzaghi C, Xu M, Salvemini L, De Bonis C, Palladino G, Huang T, Copetti M, Zheng Y, Li Y, Fini G. Circulating adiponectin and cardiovascular mortality in patients with type 2 diabetes mellitus: evidence of sexual dimorphism. Cardiovasc Diabetol. 2014;13:130.
37. Tamba SM, Ewane ME, Bonny A, Muisi CN, Nana E, Ellong A, Mvogo CE, Mandengue SH. Micro and macrovascular complications of diabetes mellitus in Cameroon: risk factors and effect of diabetic check-up-a monocentric observational study. Pan African Med J. 2013;15:141.
38. Boonman-de Winter LJ, Rutten FH, Cramer MJ, Landman MJ, Liem AH, Rutten GE, Hoes AW. High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes. Diabetologia. 2012;55:2154-62.
39. Wentworth JM, Fourlanos S, Colman PG. Body mass index correlates with ischemic heart disease and albuminuria in long-standing type 2 diabetes. Diab Res Clin Pract. 2012;97:57-62.
40. Glogner S, Rosengren A, Olsson M, Gudbjörnsdottir S, Svensson AM, Lind M. The association between BMI and hospitalization for heart failure in 83,021 persons with Type 2 diabetes: a population-based study from the Swedish National Diabetes Registry. Diab Med. 2014;31:586-94.
41. Alaboud AF, Tourkmani AM, Alharbi TJ, Alobikan AH, Abdelhay O, Al Batal SM, Alkashan HI, Mohammed UY. Microvascular and macrovascular complications of type 2 diabetic mellitus in Central, Kingdom of Saudi Arabia. Saudi Med J. 2016;37:1408-11.
42. Alonso-Moran E, Orueta JF, Fraile Esteban JI, Arteagoitia Axpe JM, Marques Gonzalez ML, Toro Polanco N, Ezkurra Loiola P, Gaztambide S, Nuno-Solinis R. The prevalence of diabetes-related complications and multimorbidity in the population with type 2 diabetes mellitus in the Basque Country. BMC Public Health. 1059;2014:14.
43. Carrasco-Sánchez FJ, Gomez-Huelgas R, Formiga F, Conde-Martel A, Trullàs JC, Bettencourt P, Arévalo-Lorido JC, Pérez-Barquero MM. Association between type-2 diabetes mellitus and post-discharge outcomes in heart failure patients: findings from the RICA registry. Diabetes Res Clin Pract. 2014;104:410-9.
44. Gregg EW, Cheng YJ, Saydah S, Cowie C, Garfield S, Geiss L, Barker L. Trends in death rates among US adults with and without diabetes between 1997 and 2006. Diab Care. 2012;35:1252-7.
45. Lin PJ, Cohen JT, Kent WA, Neumann PJ. Patterns of comorbidity clusters among adults with diabetes. Value Health. 2013;16:A155-6.
46. Song S, Hardisty C. Early onset type 2 diabetes mellitus: a harbinger for complications in later years-clinical observation from a secondary care cohort. QJM. 2009;102:799-806.
47. Yang HK, Kang B, Lee S-H, Yoon K-H, Hwang B-H, Chang K, Han K, Kang G, Cho JH. Association between hemoglobin A1c variability and subclinical coronary atherosclerosis in subjects with type 2 diabetes. J Diab Complications. 2015;29:776-82.
48. Mansour AA, Ajeel NA. Atherosclerotic cardiovascular disease among patients with type 2 diabetes in Basrah. World J Diab. 2013;4:82.
49. Menghua Z. GW25-e1447 clinical significance of multislice coronary CT angiography in asymptomatic patients with type 2 diabetes mellitus. J Am Coll Cardiol. 2014;64:C227.
50. Norhammar A, Bodegard J, Nystrom T, Thuresson M, Eriksson JW, Nathanson D. Incidence, prevalence and mortality of type 2 diabetes requiring glucose-lowering treatment, and associated risks of cardiovascular complications: a nationwide study in Sweden, 2006-2013. Diabetologia. 2016;59:1692-701.
51. Rossi MC, Lucisano G, Comaschi M, Coscelli C, Cucinotta D, Di Blasi P, Bader G, Pellegrini F, Valentini U, Vespasiani G. Quality of diabetes care predicts the development of cardiovascular events: results of the AMD-QUASAR study. Diab Care. 2011;34:347-52.
52. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart study. Circulation. 1983;67:968-77.
53. Rabkin SW, Mathewson FA, Hsu PH. Relation of body weight to development of ischemic heart disease in a cohort of young North American men after a 26 year observation period: the Manitoba study. Am J Cardiol. 1977;39:452-8.
54. Garcia-Labbe D, Ruka E, Bertrand OF, Voisine P, Costerousse O, Poirier P. Obesity and coronary artery disease: evaluation and treatment. Can J Cardiol. 2015;31:184-94.
55. Plourde B, Sarrazin JF, Nault I, Poirier P. Sudden cardiac death and obesity. Exp Rev Cardiovasc Ther. 2014;12:1099-110.
56. Engeland A, Bjorge T, Sogaard AJ, Tverdal A. Body mass index in adolescence in relation to total mortality: 32-year follow-up of 227,000 Norwegian boys and girls. Am J Epidemiol. 2003;157:517-23.
57. Masmiquel L, Leiter L, Vidal J, Bain S, Petrie J, Franek E, Raz I, Comlekci A, Jacob S. Gaal Lv: LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial. Cardiovasc Diabetol. 2016;15:29.
58. World Health Organization. Obesity and Overweight. Factsheet No 311. Geneva: World Health Organization; 2017.
59. Gujral UP, Pradeepa R, Weber MB, Narayan KM, Mohan V. Type 2 diabetes in South Asians: similarities and differences with white Caucasian and other populations. Ann N Y Acad Sci. 2013;1281:51-63.
60. Raji A, Seely EW, Arky RA, Simonson DC. Body fat distribution and insulin resistance in healthy Asian Indians and Caucasians. J Clin Endocrinol Metab. 2001;86:5366-71.
61. Huxley R, James W, Barzi F, Patel J, Lear S, Suriyawongpaisal P, Janus E, Caterson I, Zimmet P, Prabhakaran D. Ethnic comparisons of the cross-sectional relationships between measures of body size with diabetes and hypertension. Obes Rev. 2008;9:53-61.
62. World Health Organization Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363:157.
63. Koellhoffer EC, McCullough LD. The effects of estrogen in ischemic stroke. Transl Stroke Res. 2013;4:390-401.
64. Meseguer A, Puche C, Cabero A. Sex steroid biosynthesis in white adipose tissue. Horm Metab Res. 2002;34:731-6.
65. Hartrumpf M, Kuehnel RU, Albes JM. The obesity paradox is still there: a risk analysis of over 15,000 cardiosurgical patients based on body mass index. Interact Cardiovasc Thorac Surg. 2017;25:18-24.
66. Lee KS, Moser DK, Lennie TA, Pelter MM, Nesbitt T, Southard JA, Dracup K. Obesity paradox: comparison of heart failure patients with and without comorbid diabetes. Am J Crit Care. 2017;26:140-8.
67. Abi Khalil C, Sulaiman K, Singh R, Jayyousi A, Asaad N, AlHabib KF, Alsheikh-Ali A, Al-Jarallah M, Bulbanat B, Al Mahmeed W, et al. BMI is inversely correlated to the risk of mortality in patients with type 2 diabetes hospitalized for acute heart failure: findings from the Gulf aCute heArt failuRE (Gulf-CARE) registry. Int J Cardiol. 2017;5273(0116):34386-8.
68. Straka RJ, Liu LZ, Girase PS, DeLorenzo A, Chapman RH. Incremental cardiovascular costs and resource use associated with diabetes: an assessment of 29,863 patients in the US managed-care setting. Cardiovasc Diabetol. 2009;8:53.
69. Senthil AN, Ravishankar G, Ravi MS, Meenakshi K, Muthu Kumar D, Swaminathan N, Paul J, Venkatesan S. Pattern of coronary artery disease in symptomatic Type 2 diabetic subjects in the contemporary era and the difference from past studies. Indian Heart J. 2014;66:S46.
70. Nair M, Prabhakaran D. Why do South Asians have high risk for CAD? Global Heart. 2012;7:307-14.
71. Azoulay L, Suissa S. Sulfonylureas and the risks of cardiovascular events and death: a methodological meta-regression analysis of the observational studies. Diab Care. 2017;40:706-14.
72. World Health Organization. Global status report on noncommunicable diseases. Geneva: World Health Organization; 2014. p. 1-302.
73. Jung CH, Chung JO, Han K, Ko S-H, Ko KS, Park J-Y. Improved trends in cardiovascular complications among subjects with type 2 diabetes in Korea: a nationwide study (2006-2013). Cardiovasc Diabetol. 2017;16:1.
74. Huang Y, Li J, Zhu X, Sun J, Ji L, Hu D, Pan C, Tan W, Jiang S, Tao X. Relationship between healthy lifestyle behaviors and cardiovascular risk factors in Chinese patients with type 2 diabetes mellitus: a subanalysis of the CCMR-3B STUDY. Acta Diabetol. 2017;54:569-79.
75. Simmons RK, Griffin SJ, Lauritzen T, Sandbæk A. Effect of screening for type 2 diabetes on risk of cardiovascular disease and mortality: a controlled trial among 139,075 individuals diagnosed with diabetes in Denmark between 2001 and 2009. Diabetologia. 2017;60:2192-9.
76. Simmons RK, Griffin SJ, Witte DR, Borch-Johnsen K, Lauritzen T, Sandbæk A. Effect of population screening for type 2 diabetes and cardiovascular risk factors on mortality rate and cardiovascular events: a controlled trial among 1,912,392 Danish adults. Diabetologia. 2017;60:2183-91.
77. Kelsall HL, Fernando PHS, Gwini SM, Sim MR. Cardiovascular disease and type 2 diabetes risk across occupational groups and industry in a statewide study of an Australian working population. J Occup Environ Med. 2018;60:286-94.
78. Li M-F, Zhao C-C, Li T-T, Tu Y-F, Lu J-X, Zhang R, Chen M-Y, Bao Y-Q, Li L-X, Jia W-P. The coexistence of carotid and lower extremity atherosclerosis further increases cardio-cerebrovascular risk in type 2 diabetes. Cardiovasc Diabetol. 2016;15:43.
79. Mohammedi K, Woodward M, Marre M, Colagiuri S, Cooper M, Harrap S, Mancia G, Poulter N, Williams B, Zoungas S. Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetes. Cardiovasc Diabetol. 2017;16:95.
80. Malik S, Zhao Y, Budoff M, Nasir K, Blumenthal RS, Bertoni AG, Wong ND. Coronary artery calcium score for long-term risk classification in individuals with type 2 diabetes and metabolic syndrome from the multi-ethnic study of atherosclerosis. JAMA Cardiol. 2017;2:1332-40.
81. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-504.
82. Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart J-C, Haffner S, Hsia J, Breazna A, LaRosa J, Grundy S. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the treating to new targets (TNT) study. Diab Care. 2006;29:1220-6.
83. Stein EA, Lane M, Laskarzewski P. Comparison of statins in hypertriglyceridemia. Am J Cardiol. 1998;81:66B-9B.
84. Ren Y, Ren Q, Lu J, Guo X, Huo X, Ji L, Yang X. Low triglyceride as a marker for increased risk of cardiovascular diseases in patients with long-term type 2 diabetes: a cross-sectional survey in China. Diab Metab Res Rev. 2018;34:e2960.
85. Clua-Espuny JL, González-Henares MA, Queralt-Tomas MLL, et al. Mortality and cardiovascular complications in older complex chronic patients with type 2 diabetes. BioMed Res Int. 2017;2017:6078498.
86. Cheng Y, Zhang H, Chen R, Yang F, Li W, Chen L, Lin S, Liang G, Cai D, Chen H. Cardiometabolic risk profiles associated with chronic complications in overweight and obese type 2 diabetes patients in South China. PLoS ONE. 2014;9:e101289.
87. Cortez-Dias N, Martins S, Belo A, Fiuza M. em nome dos Investigadores do Estudio VALSIM: prevalência, tratamento e controlo da diabetes mellitus e dos factores de risco associados nos cuidados de saúde primários em Portugal. Rev Port Cardiol. 2010;29:509-37.
88. Daghash MH, Bener A, Zirie M, Dabdoob W, Al-Hamaq AO, Al-Arabi ZA. Lipoprotein profile in Arabian type 2 diabetic patients. relationship to coronary artery diseases. Int J Cardiol. 2007;121:91-2.
89. Doucet JA, Bauduceau B, Le Floch JP, Verny C. Medical treatments of elderly, French patients with type 2 diabetes: results at inclusion in the GERODIAB Cohort. Fundam Clin Pharmacol. 2016;30:76-81.
90. Farrell C, Moran J. Comparison of comorbidities in patients with pre-diabetes to those with diabetes mellitus type 2. IMJ. 2014;3:107.
91. Fu AZ, Qiu Y, Radican L, Yin DD, Mavros P. Impact of concurrent macrovascular co-morbidities on healthcare utilization in patients with type 2 diabetes in Europe: a matched study. Diab Obes Metab. 2010;12:631-7.
92. Giallauria F, Fattirolli F, Tramarin R, Ambrosetti M, Griffo R, Riccio C, De Feo S, Piepoli MF, Vigorito C. Clinical characteristics and course of patients with diabetes entering cardiac rehabilitation. Diab Res Clin Pract. 2015;107:267-72.
93. Gobardhan SN, Dimitriu-Leen AC, van Rosendael AR, van Zwet EW, Roos CJ, Oemrawsingh PV, Kharagjitsingh AV, Jukema JW, Delgado V, Schalij MJ. Prevalence by computed tomographic angiography of coronary plaques in South Asian and white patients with type 2 diabetes mellitus at low and high risk using four cardiovascular risk scores (UKPDS, FRS, ASCVD, and JBS3). Am J Cardiol. 2017;119:705-11.
94. Gondim F, Caribé A, Vasconcelos KF, Segundo AD, Bandeira F. Vitamin D deficiency is associated with severity of acute coronary syndrome in patients with type 2 diabetes and high rates of sun exposure. Clin Med Insights. 2016;9:37.
95. Hermans MP, Bouenizabila E, Ahn SA, Rousseau MF. How to transform a metabolic syndrome score into an insulin sensitivity value? Diab Metab Res Rev. 2016;32:87-94.
96. Hunt KJ, Kistner-Griffin E, Spruill I, Teklehaimanot AA, Garvey WT, Sale M, Fernandes J. Cardiovascular risk in Gullah African Americans with high familial risk of type 2 diabetes mellitus: project SuGAR. South Med J. 2014;107:607-14.
97. Jackson CA, Jones NR, Walker JJ, Fischbacher CM, Colhoun HM, Leese GP, Lindsay RS, McKnight JA, Morris AD, Petrie JR, et al. Area-based socioeconomic status, type 2 diabetes and cardiovascular mortality in Scotland. Diabetologia. 2012;55:2938-45.
98. Jurado J, Ybarra J, Solanas P, Caula J, Gich I, Pou JM, Romeo JH. Prevalence of cardiovascular disease and risk factors in a type 2 diabetic population of the North Catalonia diabetes study. J Am Acad Nurse Pract. 2009;21:140-8.
99. Kucharska-Newton AM, Couper DJ, Pankow JS, Prineas RJ, Rea TD, Sotoodehnia N, Chakravarti A, Folsom AR, Siscovick DS, Rosamond WD. Diabetes and the risk of sudden cardiac death, the atherosclerosis risk in communities study. Acta Diabetol. 2010;47(Suppl 1):161-8.
100. Kwon H, Lim J, Shin J, Son J, Lee S, Kim S, Yoo S. A relationship of asymptomatic coronary artery disease and type 2 diabetes in acute ischaemic stroke patients; cerebral angiography and coronary angiography study. Diabetoligia. 2014;57:S26.
101. Liu X, Liu Y, Lv Y, Li C, Cui Z, Ma J. Prevalence and temporal pattern of hospital readmissions for patients with type I and type II diabetes. BMJ Open. 2015;5:e007362.
102. Luo Y, Wang X, Wang Y, Wang C, Wang H, Wang D, Liu L, Jia Q, Liu G, Zhao X, et al. Association of glomerular filtration rate with outcomes of acute stroke in type 2 diabetic patients: results from the China National Stroke Registry. Diab Care. 2014;37:173-9.
103. MacDonald MR, Petrie MC, Home PD, Komajda M, Jones NP, Beck-Nielsen H, Gomis R, Hanefeld M, Pocock SJ, Curtis PS, McMurray JJ. Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the rosiglitazone evaluated for cardiac outcomes and regulation of glycemia in diabetes (RECORD) study. Diab Care. 2011;34:1394-6.
104. Mazza A, Zamboni S, Rizzato E, Pessina AC, Tikhonoff V, Schiavon L, Casiglia E. Serum uric acid shows a J-shaped trend with coronary mortality in non-insulin-dependent diabetic elderly people. The CArdiovascular STudy in the ELderly (CASTEL). Acta Diabetol. 2007;44:99-105.
105. Mody R, Kalsekar I, Kavookjian J, Iyer S, Rajagopalan R, Pawar V. Economic impact of cardiovascular co-morbidity in patients with type 2 diabetes. J Diab Complications. 2007;21:75-83.
106. Mundet X, Cano F, Mata-Cases M, Roura P, Franch J, Birules M, Gimbert R, Llusa J, Cos X. Trends in chronic complications of type 2 diabetic patients from Spanish primary health care centres (GEDAPS study): 10 year-implementation of St. Vincent recommendations. Prim Care Diab. 2012;6:11-8.
107. Narksawat K, Sujirarat D, Panket P. Combined effects of hypertension and diabetes mellitus with stroke among Thais in the central region of Thailand: a cross-sectional study. J Med Assoc Thai. 2013;5:S1-7.
108. Penno G, Solini A, Zoppini G, Fondelli C, Trevisan R, Vedovato M, Cavalot F, Gruden G, Lamacchia O, Laviola L. Independent correlates of urinary albumin excretion within the normoalbuminuric range in patients with type 2 diabetes: the renal insufficiency and cardiovascular events (RIACE) Italian multicentre study. Acta Diabetol. 2015;52:971-81.
109. Rodriguez-Poncelas A, Coll-De Tuero G, Turro-Garriga O, Barrot-de la Puente J, Franch-Nadal J, Mundet-Tuduri X, Red GSG. Impact of chronic kidney disease on the prevalence of cardiovascular disease in patients with type 2 diabetes in Spain: PERCEDIME2 study. BMC Nephrol. 2014;15:150.
110. Soetedjo N, Permana H, Ruslami R, Livia R, Panduru N, Critchley J, Hulscher M, Tack C, Alisjahbana B, van Crevel R. PO035 High prevalence of macrovascular complications and insufficient cardiovascular management in indonesian diabetes patients; a hospital survey. Diab Res Clin Pract. 2014;106:S63.
111. Suh DC, Kim CM, Choi IS, Plauschinat CA. Comorbid conditions and glycemic control in elderly patients with type 2 diabetes mellitus, 1988 to 1994 to 1999 to 2004. J Am Geriatr Soc. 2008;56:484-92.
112. Utrera-Lagunas M, Orea-Tejeda A, Castillo-Martinez L, Balderas-Munoz K, Keirns-Davis C, Espinoza-Rosas S, Sanchez-Ortiz NA, Olvera-Mayorga G. Abnormal myocardial perfusion and risk of heart failure in patients with type 2 diabetes mellitus. Exp Clin Cardiol. 2013;18:e44-6.
113. Vinagre I, Mata-Cases M, Hermosilla E, Morros R, Fina F, Rosell M, Castell C, Franch-Nadal J, Bolibar B, Mauricio D. Control of glycemia and cardiovascular risk factors in patients with type 2 diabetes in primary care in Catalonia (Spain). Diab Care. 2012;35:774-9.
114. Wong K, Glovaci D, Malik S, Franklin SS, Wygant G, Iloeje U, Kan H, Wong ND. Comparison of demographic factors and cardiovascular risk factor control among US adults with type 2 diabetes by insulin treatment classification. J Diab Complications. 2012;26:169-74.
115. Yan BP, Zhang Y, Kong AP, Luk AO, Ozaki R, Yeung R, Tong PC, Chan WB, Tsang C-C, Lau K-P. Borderline ankle-brachial index is associated with increased prevalence of micro-and macrovascular complications in type 2 diabetes: a cross-sectional analysis of 12,772 patients from the Joint Asia Diabetes Evaluation Program. Diab Vasc Dis Res. 2015;12:334-41.
116. Zekry D, Frangos E, Graf C, Michel JP, Gold G, Krause KH, Herrmann FR, Vischer UM. Diabetes, comorbidities and increased long-term mortality in older patients admitted for geriatric inpatient care. Diab Metab. 2012;38:149-55.
117. World Bank. GNI ranking, atlas method. http://data.worldbank.org/data-catalog/GNI-per-capita-Atlas-and-PPP-table. Accessed 26 Apr 2017.
118. World Bank. The data blog: New country classifications by income level. https://blogs.worldbank.org/opendata/new-countryclassifications-2016. Accessed 26 Apr 2017.